topic

611 XTX202–01/02–001, Phase 1/2 first-in human study of XTX202, a masked, tumor-activated IL-2βγ, in patients with advanced solid tumors: results from phase 1
Diana Hanna, Yousef Zakharia, Sanjay Goel, Randy Hurley, Meredith Pelster, Anthony El-Khoueiry, Jacob Thomas, John Powderly, David Miller, Richard Wu, Bartosz Chmielowski, Suthee Rapisuwon, Anurag Gupta, Meghan Duncan, Aika Siu, Ekta Patel, Damiano Fantini, David Crowe, Sattanathan Paramasivan, George Lee, Katarina Luptakova, Meredith McKean

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A695-A696; DOI: 10.1136/jitc-2023-SITC2023.0611
612 Lymphodepletion blunts the antigen-spreading response post TAA-T cell therapy for pediatric solid tumors
Amy B Hont, Naomi Field, Samantha Murphy, Conrad Cruz, Patrick J Hanley, Chase D McCann, Haili Lang, Anushree Datar, Rachel DiCioccio, Fahmida Hoq, Catherine M Bollard, Holly J Meany

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A697; DOI: 10.1136/jitc-2023-SITC2023.0612
613 A phase II study of nivolumab in patients with genetic alterations in DNA damage repair and response who progressed after standard treatment for metastatic solid cancers (KM-06)
Ju Won Kim, Hyo Jin Lee, Ji Yoon Lee, Jason K Sa, Sook Ryun Park, Yu Kim, In Gyu Hwang, Woo Kyun Bae, Jae Ho Byun, Jung Sun Kim, Eun Joo Kang, Jeeyun Lee, Sang Shin, Kyong Hwa Park

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A698; DOI: 10.1136/jitc-2023-SITC2023.0613
614 Safety and efficacy of YBL-006, a novel anti-PD-1 antibody, in advanced solid tumors including G3 NET/NEC: results from a phase 1/2A study
Keun-Wook Lee, John Park, Seung-Tae Kim, Virote Sriuranpong, Sun Young Rha, Changhoon Yoo, Sehyun Kim, Bhumsuk Keam, Dhanusha Sabanathan, Joon Oh Park, Napa Parinyanitikul, Min Hwan Kim, Kyu Pyo Kim, Chan-Young Ock, Jaebong Yoon, Hyelim Lim, Sangheon Lee, Wooick Jang, Do-Youn Oh

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A699; DOI: 10.1136/jitc-2023-SITC2023.0614
615 The impact of gender including female menopausal status on the safety and efficacy of immune checkpoint inhibitors
Shaked Lev Ari, Jacob Zaemes, Deniz Ozisik, Rachel A Zemel, Ming Tan, Lauren Pascual, Brittany Sinclaire, Adil Alaoui, Alexandra DellaPia, Andrew Pecora, Michael B Atkins, Andrew Ip, Neil J Shah

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A700; DOI: 10.1136/jitc-2023-SITC2023.0615
616 Pharmacokinetics and safety of a subcutaneous formulation of nivolumab (NIVO SC) monotherapy: updated results from the phase 1/2 CheckMate 8KX study
Sara Lonardi, Iwona Ługowska, Anne O’Donnell, Christopher Jackson, Loes Maria Latten-Jansen, Richard North, Marcelo Garrido Salvo, Armando Santoro, Matías Chacón, Linghui Li, Devanand Joseph, Elizabeth Gibson, Bryan Bennett, Balmeet Gurm, Wee-Teck Ng, R Donald Harvey, José Manuel Trigo Pérez, Aitana Calvo

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A701-A702; DOI: 10.1136/jitc-2023-SITC2023.0616
617 A Phase I study of a tumor-targeted, fibroblast activation protein (FAP)-CD40 agonist (RO7300490) in patients with advanced solid tumors
Ignacio Melero, Maria Lostes Baradji, Iben Spanggaard, Dae Lee, James Spicer, Fiona C Thistlethwaite, Stefan Symeonides, Do-Youn Oh, Antoine Hollebecque, Corinne Rusterholz, Olivera Cirovic, Yvonne Zhao, Nicole Kratochwil, Bernhard Reis, Alexandra Epp, Georgios Kazantzidis, Victor Moreno

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A703; DOI: 10.1136/jitc-2023-SITC2023.0617
618 Phase 1 clinical trial evaluating the safety, biologic and anti-tumor activity of the novel STING agonist IMSA101 administered both as monotherapy and in combination with PD-(L)1 checkpoint inhibitors
Justin C Moser, Angela Alistar, Ezra Cohen, Edward Garmey, Syed Kazmi, Teresa Mooneyham, Lijun Sun, Timothy Yap, Devalingam Mahalingam

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A704; DOI: 10.1136/jitc-2023-SITC2023.0618
619 First-in-class anti-CD200R1 antibody 23ME-00610 in patients with advanced solid malignancies: updated phase 1 results
Drew Rasco, Albiruni Abdul Razak, Scott A Laurie, Anh Diep, Dylan M Glatt, Sophia R Majeed, Shivaani Kummar

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A705; DOI: 10.1136/jitc-2023-SITC2023.0619
620 Multimodal real world data reveals immunogenomic drivers of acquired and primary resistance to immune checkpoint blockade
Mohamed Reda Keddar, Sebastian Carrasco Pro, Kathleen Burke, Roy Rabbie, Ana Stewart, Mark Cobbold, Ross Stewart, Benjamin Sidders, Sajan Khosla, Scott Hammond, Douglas C Palmer, Jonathan R Dry, Martin L Miller

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A706-A707; DOI: 10.1136/jitc-2023-SITC2023.0620

Main menu

topic

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

topic

Pages